HYAL4 and urinary bladder carcinoma: The v1 protein variant also showed chemotherapeutic resistance to Gemcitabine in preclinical models, suggesting HYAL4 drives chemoresistance in bladder cancer (Lokeshwar et al., 2020; Hasanali et al., 2021).